brainsway is a leading global neurmodulation company with headquarters in jerusalem and the us. our patented breakthrough technology has already treated over 10,000 patients, and has helped usher in a new era in brain disorder treatment. a non-invasive, yet highly effective solution for brain disorders, brainsway has helped thousands of patients across the world, from the unites states to europe to south america, and has the potential to make a difference in the well-being and health of millions of patients worldwide. brainsway's technology offers a much needed alternative for millions of patients from a bleak cycle of insufficiently effective treatments and unpleasant side effects. brainsway's treatment has fda approval for treating patients with major depressive disorder*. the technology is safe, with no systemic or long-term side effects, in addition to being highly convenient, requiring only brief daily sessions over a few weeks. in addition to being used to treat depression daily
Company profile
Ticker
BWAY, BRSYF
Exchange
Website
CEO
Christopher von Jako
Employees
Incorporated
Location
Industry (SIC)
SEC CIK
BWAY stock data
Latest filings (excl ownership)
6-K
Company Announces 11th Recent System Installed in Israel, with More Expected this Year
17 Apr 24
6-K
BrainsWay Announces Published Review Results Highlighting Potential of Deep TMS™ to Treat Parkinson's Disease
4 Apr 24
20-F
2023 FY
Annual report (foreign)
28 Mar 24
6-K
BrainsWay Broadens Partnership with Katie’s Way Plus Through Order of an Additional 18 Deep TMS™ Systems
18 Mar 24
6-K
BrainsWay Reports Fourth Quarter and Full-Year 2023 Financial Results and Operational Highlights
6 Mar 24
6-K
Current report (foreign)
10 Jan 24
6-K
BrainsWay Highlights Expanded Deep TMS™ Access with Growing Western U.S. Network
19 Dec 23
6-K
Current report (foreign)
20 Nov 23
6-K
BrainsWay Reports Third Quarter 2023 Financial Results and Operational Highlights
15 Nov 23
6-K
Clinical TMS Society Publishes First Coverage Recommendations for the Treatment of Smoking Addiction
2 Nov 23
Latest ownership filings
SC 13G/A
HIRSCHMAN ORIN
21 Feb 24
SC 13G/A
RTW INVESTMENTS, LP
14 Feb 24
SC 13G/A
HIRSCHMAN ORIN
7 Feb 24
SC 13G
HIRSCHMAN ORIN
14 Jun 23
SC 13G/A
Phoenix Holdings Ltd.
3 Apr 23
SC 13G/A
Phoenix Holdings Ltd.
14 Feb 23
SC 13G/A
MASTERS CAPITAL MANAGEMENT LLC
14 Feb 23
SC 13G/A
Cowen Financial Products LLC
18 Jan 23
SC 13G
Zacut David
30 Nov 22
SC 13G
Hagai Avner
30 Nov 22
Financial summary
Quarter (USD) | Dec 22 | Dec 21 | Dec 20 | Dec 19 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 22 | Dec 21 | Dec 20 | Dec 19 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Institutional ownership, Q3 2023
32.3% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 16 |
Opened positions | 2 |
Closed positions | 3 |
Increased positions | 6 |
Reduced positions | 2 |
13F shares | Current |
---|---|
Total value | 15.78 bn |
Total shares | 5.38 mm |
Total puts | 0.00 |
Total calls | 0.00 |
Total put/call ratio | – |
Largest owners | Shares | Value |
---|---|---|
AIGH Capital Management | 1.36 mm | $5.47 bn |
Hirschman Orin | 1.01 mm | $2.24 mm |
Masters Capital Management | 900.00 k | $3.64 bn |
PXGPE Phoenix | 836.90 k | $3.38 bn |
DAFNA Capital Management | 432.18 k | $1.75 bn |
Cowen Financial Products | 345.00 k | $852.00 k |
Worth Venture Partners | 336.64 k | $1.36 bn |
Psagot Value | 61.59 k | $244.00 k |
Renaissance Technologies | 52.50 k | $212.00 k |
Good Life Advisors | 38.72 k | $156.43 mm |
News
BrainsWay Expands Deep TMS Access In Israel; BrainsWay Has Steadily Increased Its Presence In The Country With 11 Recent System Installations, Driven In Part By A 45% Increase In Reimbursement Rates
17 Apr 24
BrainsWay Announces Published Review Results Highlighting Potential Of Deep TMS To Treat Parkinson's Disease
4 Apr 24
HC Wainwright & Co. Maintains Buy on BrainsWay, Raises Price Target to $13
11 Mar 24
BrainsWay Q4 Sales $9.03M Beat $8.42M Estimate
6 Mar 24
Earnings Scheduled For March 6, 2024
6 Mar 24
Press releases
BrainsWay Announces Positive Results in Late-Life Depression Post-Marketing Analysis
28 Mar 24
BrainsWay Broadens Partnership with Katie's Way Plus Through Order of an Additional 18 Deep TMS™ Systems
18 Mar 24
BrainsWay Reports Fourth Quarter and Full-Year 2023 Financial Results and Operational Highlights
6 Mar 24
BrainsWay to Report Fourth Quarter and Full Year 2023 Financial Results on March 6, 2024
21 Feb 24